Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
复制标题
DOI：
10.1038/leu.2017.9
复制
发表时间：
2017-04-01
期刊：
影响因子：
11.4
通讯作者：
Burchert, A.
中科院分区：
文献类型：
--
作者：
Schuetz, C.;Inselmann, S.;Burchert, A.
目前尚不清楚为什么只有少数慢性粒细胞白血病（CML）患者在深度分子缓解（MR）中停止酪氨酸激酶抑制剂（TKI）治疗后仍能维持无治疗缓解（TFR）。在这里，我们研究了浆细胞样树突状细胞（pDC）上T细胞抑制性受体（CTLA-4）-配体CD 86（B7.2）的表达是否会影响TKI停止后的复发风险。CML患者MR中CD 86 + pDC频率显著高于正常人（P
It is unknown, why only a minority of chronic myeloid leukemia (CML) patients sustains treatment free remission (TFR) after discontinuation of tyrosine kinase inhibitor (TKI) therapy in deep molecular remission (MR). Here we studied, whether expression of the T-cell inhibitory receptor (CTLA-4)-ligand CD86 (B7.2) on plasmacytoid dendritic cells (pDC) affects relapse risk after TKI cessation. CML patients in MR displayed significantly higher CD86+ pDC frequencies than normal donors (P